Sector Pharmaceuticals & Biotech. - Latest news, views and updates

Pharmaceuticals & Biotech.

SECTOR | 09 Jul 2025

Stocks To Watch Today: JSW Steel, Tata Steel, Zee, NTPC, Pharma Companies

NDTV Profit

NTPC and Puravankara are also some of the stocks to watch on Wednesday.

Pharmaceuticals & Biotech.

SECTOR | 09 Jul 2025

Q1FY26 Earnings Preview - Pharma and Healthcare

Pharmaceuticals & Biotech.

Axis Direct

Q1FY26 Earnings Preview - Pharma & Healthcare

Pharmaceuticals & Biotech.

SECTOR | 08 Jul 2025

Q1FY26E Pharmaceuticals Sector Preview

Pharmaceuticals & Biotech.

Deven Choksey

As per Pharma rack data, during Apr’25, the Indian pharmaceutical market (IPM) grew by 7.8% YoY, led by improved price realization (+5.1% YoY), modest new launches (+2.3% YoY), and muted volume growth (+0.4% YoY).

Pharmaceuticals & Biotech.

SECTOR | 07 Jul 2025

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Business Standard

Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for Vevzuo and Evfraxy, biosimilars of Denosumab used in the treatment of bone-related diseases. Vevzuo is authorised for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, Biocon said in a regulatory filing. It is also authorised for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. On the other hand, Evfraxy is authorised for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, the company said. In postmenopausal women, this significantly reduces the risk of vertebral, non-vertebral, and hip fractures, it...

Pharmaceuticals & Biotech.

SECTOR | 03 Jul 2025

Biocon Biologics Granted Marketing Authorisation By European Commission For Bone Disease Medicines

NDTV Profit

Biocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.

Pharmaceuticals & Biotech.

SECTOR | 27 Jun 2025

Govt, industry hold talk on issues over marketing code for medical devices

Business Standard

Medical device companies raise issues with the DoP over UDMPMD norms related to disclosure of training expenses and restrictions on overseas training approvals

Pharmaceuticals & Biotech.

SECTOR | 25 Jun 2025

CDSCO relaxes loan license requirement for med device sterilisation

Business Standard

Medical device makers can now outsource sterilisation through third-party agreements without loan licences if the facility holds a valid sterilisation licence

Pharmaceuticals & Biotech.

SECTOR | 20 Jun 2025

USFDA approves first HIV prevention shot needing only two doses a year

Business Standard

Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution and near-complete protection to boost global HIV prevention efforts

Pharmaceuticals & Biotech.

SECTOR | 12 Jun 2025

More than 460 laid-off CDC employees receive reinstatement notices

Business Standard

More than 460 laid-off employees at the nation's top public health agency received notices on Wednesday that they are being reinstated, according to a union representing the workers. The US Department of Health and Human Services confirmed reinstatement notices went out to the former Centres for Disease Control and Prevention employees, but provided few details. About 2,400 CDC employees lost their jobs in a wave of cuts across federal health agencies in early April, according to a tally at the time. Whole CDC programmes were essentially shut down, including some focused on smoking, lead poisoning, gun violence, asthma and air quality, and workplace safety and health. The entire office that handles Freedom of Information Act requests was shuttered. Infectious disease programmes took a hit, too, including programmes that fight outbreaks in other countries, labs focused on HIV and hepatitis in the US, and staff trying to eliminate tuberculosis. An estimated 200 of the reinstated work

Pharmaceuticals & Biotech.

SECTOR | 09 Jun 2025

Glenmark set to launch blood cancer treatment drug Brukinsa in India

Business Standard

Glenmark will introduce Brukinsa, a BTK inhibitor developed by BeOne Medicines, in India after DCGI approval to treat five B-cell blood cancers with proven safety and efficacy

Glenmark Pharmaceuticals poised to launch Zanubrutinib in India

Business Line | 09 Jun 2025